• 南宫NG·28

    CN
    News & Reports

    News and Reports

    Select year

    2025 2024 2023 2022 2021 Earlier
    shown/page
    5
    5 10 15 20

    2024.10.17

    Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
    Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

    Full text

    2024.10.15

    Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
    Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

    Full text

    2024.04.30

    National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
    National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

    Full text

    2024.03.18

    Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
    Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

    Full text

    2024.03.04

    CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer
    CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer

    Full text

    Media contact

    Media contact

    • Media contact

      （+86）0755-36993500

    • Media contact

      pr@makeey.com